Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.

Authors
Verweij, J
Judson, I
Steward, William P
Coleman, R
Woll, Penella J
Van Pottelsberghe, C
Van Glabbeke, Martine M
Mouridsen, H
Affiliation
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Issue Date
1994

Metadata
Show full item record
Abstract
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.
Citation
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. 1994, 30A (6):842-3 Eur. J. Cancer
Journal
European Journal of Cancer
URI
http://hdl.handle.net/10541/97145
DOI
10.1016/0959-8049(94)90303-4
PubMed ID
7917546
Type
Article
Language
en
ISSN
0959-8049
Collections